2026-08-05T15:04:37Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/51632024-09-27T08:39:23Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Fuster, Valentin
author
Gambus, Francesc
author
Patriciello, Aldo
author
Hamrin, Margaretha
author
Grobbee, Diederick E.
funder
Ferrer Internacional
2017-10-20T10:33:50Z
2017-10-20T10:33:50Z
2017
BMC Pharmacol Toxicol. 2017; 18(1):10
10.1186/s40360-016-0102-9
2050-6511
BMC Pharmacoloty & Toxicology
28166827
http://hdl.handle.net/20.500.12105/5163
Background: Cardiovascular disease (CVD) is a major cause of disability and premature death. Despite European guidelines advocating the use of medical therapies in CVD, many patients still do not achieve the guideline-recommended treatment, which highlights the need for change and innovations in this field. This requirement has been widely recognised by the national ministries of health, several European cardiology societies, and the European Parliament, who support the initiation of strategies to improve and promote cardiovascular health. Discussion: One of the key risk factors to recurrent cardiovascular events is the lack of adherence to medication and this has been added to the agenda of the European Commission. With the intention to improve treatment adherence in CVD, polypills have been investigated and numerous studies demonstrate that they significantly improve medication adherence, which contributes to the improvement of health outcomes. In Europe, the first cardiovascular polypill, developed by a public-private partnership (CNIC-Ferrer), recently became available for general prescription as a therapy for CVD prevention. This polypill significantly improves adherence, preventing fatal and non-fatal cardiovascular events, and appears to be a cost-effective strategy to improve sustainability of the health care systems in CVD. Conclusions: Given the importance of urgent and simple solutions to restraining the pandemic nature of CVD, the polypill approach should therefore be considered by physicians and public health systems as an available and innovative option to improve cardiovascular health.
eng
ACUTE MYOCARDIAL-INFARCTION
DUAL ANTIPLATELET THERAPY
CORONARY-ARTERY-DISEASE
SECONDARY PREVENTION
COMBINATION THERAPY
DOSING FREQUENCY
VASCULAR-DISEASE
HIGH-RISK
ADHERENCE
MEDICATION
The polypill approach - An innovative strategy to improve cardiovascular health in Europe
journal article
URL
https://repisalud.isciii.es/bitstreams/eed68cc0-52f1-4dbf-aa3c-1b5a6996cf21/download
File
MD5
51b955a36adb664571899847b5d16c28
392119
application/pdf
PolypillApproachAnInnovative_2017
URL
https://repisalud.isciii.es/bitstreams/e119a3bc-b290-4d48-b514-db54df907e95/download
File
MD5
9ad749d2ab328f2d15e067d25bd9c800
48481
text/plain
PolypillApproachAnInnovative_2017.txt